This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Major histocompatibility complex class I (MHC)-associated phosphopeptides to predict clinical outcome in leukemia	Tumor-associated phosphopeptides recognized by MHC could help predict outcomes for patients with leukemia. The phosphopeptide repertoires from 11 tumor samples representing multiple leukemia types were profiled for binding to MHC molecules. In samples from patients with leukemia, immune responses to the MHC-binding phosphopeptides were decreased compared with those of healthy donors. Patients without immune responses to the phosphopeptides had decreased survival compared with those who showed immune responses to the phosphopeptides. Next steps include developing phosphopeptide antigens for cancer immunotherapy. PhosImmune Inc. is developing therapeutics and diagnostics related to this work. *SciBX* **6**(41); doi:10.1038/scibx.2013.1177 Published online Oct. 24, 2013	Patented; licensed to PhosImmune, a company spun-out of the University of Virginia School of Medicine	Cobbold, M. *et al. Sci. Transl. Med.*; published online Sept. 13, 2013; doi:10.1126/scitranslmed.3006061 **Contact:** Victor H. Engelhard, University of Virginia, Charlottesville, Va. e-mail: vhe@virginia.edu **Contact:** Mark Cobbold, University of Birmingham, Birmingham, U.K. e-mail: m.cobbold@bham.ac.uk